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Background: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large
operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to
identify genomic changes occurring after treatment.
Methods: One hundred and twenty post-menopausal patients were randomised to receive 1mg anastrozole (61 patients) or
500mg fulvestrant (59 patients) for 6 months. Genomic DNA copy number profiles were generated for a subgroup of 20 patients
before and after treatment.
Results: A total of 108 patients were evaluable for efficacy and 118 for toxicity. The objective response rate determined by
clinical palpation was 58.9% (95% CI¼ 45.0–71.9) in the anastrozole arm and 53.8% (95% CI¼ 39.5–67.8) in the fulvestrant arm.
The breast-conserving surgery rate was 58.9% (95% CI¼ 45.0–71.9) in the anastrozole arm and 50.0% (95% CI¼ 35.8–64.2) in
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the fulvestrant arm. Pathological responses 450% occurred in 24 patients (42.9%) in the anastrozole arm and 13 (25.0%) in the
fulvestrant arm. The Ki-67 score fell after treatment but there was no significant difference between the reduction in the two arms
(anastrozole 16.7% (95% CI¼ 13.3–21.0) before, 3.2% (95% CI¼ 1.9–5.5) after, n¼ 43; fulvestrant 17.1% (95%CI¼ 13.1–22.5) before,
3.2% (95% CI¼ 1.8–5.7) after, n¼ 38) or between the reduction in Ki-67 in clinical responders and non-responders. Genomic
analysis appeared to show a reduction of clonal diversity following treatment with selection of some clones with simpler copy
number profiles.
Conclusions: Both anastrozole and fulvestrant were effective and well-tolerated, enabling breast-conserving surgery in over 50%
of patients. Clonal changes consistent with clonal selection by the treatment were seen in a subgroup of patients.
Endocrine therapy is widely used to treat hormone-receptor-
positive breast cancer. Neoadjuvant endocrine therapy, where drug
treatment is given before surgery, is commonly given to elderly
patients with large operable or locally advanced hormone-receptor-
positive breast cancer because it has a favourable toxicity profile
and permits breast-conserving surgery in 40–50% of patients who
would otherwise have required mastectomy (Semiglazov et al,
2007; Mathew et al, 2009; Chia et al, 2010; Debled et al, 2014). In
this setting, treatment with aromatase inhibitors is considered as a
standard in post-menopausal patients (Eiermann et al, 2001; Smith
et al, 2005). Fulvestrant is an oestrogen receptor downregulator
with a different mechanism of action. Several trials have assessed
fulvestrant in women with metastatic breast cancer (Chia et al,
2010; Robertson et al, 2012; Robertson et al, 2014), but in the
neoadjuvant setting, there are only a few small studies comparing
500mg fulvestrant to an aromatase inhibitor (Massarweh et al,
2011).
Resistance to hormonal therapy can arise through multiple
mechanisms (reviewed by Ali and Coombes, 2002). Mutation of
the oestrogen receptor can confer estradiol-independent activation
of transcription (Weis et al, 1996) and has been identified in
metastatic breast cancers treated with hormonal therapy (reviewed
by Segal and Dowsett, 2014). Activation of growth factor signalling
pathways, leading to phosphorylation of ERa on serines 118 and
167 in the ligand-independent transactivation domain, activates
ERa in the absence of estradiol (reviewed by Ali and Coombes,
2002). Increased expression of coactivators, in particular amplifi-
cation of the NCOA3 and CCND1 genes, and decreased expression
of corepressors, are additional mechanisms of resistance to
hormonal therapy (reviewed by Ali and Coombes, 2002). Finally,
conversion to a progenitor or stem-like state in which ESR1 is not
required for growth, for example, through expression of ELF5
(Kalyuga et al, 2012) or SOX2 (Piva et al, 2014), confers oestrogen
independence. Given the wide range of mechanisms, it is possible
that resistance to fulvestrant and aromatase inhibitors could arise
through different mechanisms. An important difference between
the drugs is that aromatase inhibitors deprive the cell of oestrogen
but do not induce degradation of the receptor, whereas fulvestrant
induces ERa degradation. An increase in ERa level, for example, by
amplification of the gene, might offset a reduced availability of
ligand, leading to resistance to aromatase inhibitors. Resistance to
fulvestrant seems unlikely to arise through this mechanism.
Instead, mutations interfering with ERa degradation or activating
the pathway downstream of the receptor might be favoured with
fulvestrant. Endocrine therapy typically causes tumours to regress
over a period of several months, during which time clonal selection
may gradually occur. Unlike chemotherapy, hormonal therapy is
not clastogenic or mutagenic, so genetic changes arising during
treatment are unlikely to be secondary events provoked by
iatrogenic DNA damage. Hence, hormonal therapy given in a
neoadjuvant trial provides an ideal opportunity to study resistance
to endocrine therapy arising in vivo.
Given the lack of clinical data on fulvestrant in patients with
large operable or locally advanced hormone-receptor-positive
breast cancer, and the potential to identify differences in the
mechanism of resistance using the neoadjuvant model, we decided
to perform a multicentre randomised phase II clinical trial of
anastrozole and fulvestrant. This manuscript reports both the
clinical findings of this trial and the genomic changes arising
during endocrine therapy in the subgroup of patients for whom the
tumour cell content was at least 50% in the samples taken before
and after treatment.
METHODS
Protocol approval. The study was approved by the South-West
France and Overseas Departments, Committee for Protection of
Research Subjects (Comite´ de Protection des Personnes, Sud-Ouest
et Outre-Mer III, 2007/57) and conducted according to the
Declaration of Helsinki, EU clinical trials directives (2001/20/CE)
and Good Clinical Practice guidelines. The clinicaltrials.gov
registry number is NCT0087858. Patients gave signed informed
consent to participate in the study and to allow the use of their
tumour samples for research including genomic analysis. Samples
from the trial were stored in the Bergonie Institute Tumour Bank
in compliance with French laws on tumour banks (authorisation
no. AC-2008–812). The translational study was approved by the
French authorities (authorisation no. M70674–4201). The funders
had no role in the study design, data analysis or manuscript
drafting.
Study design. This was a non-comparative multicentre rando-
mised phase II study in which patients from three French centres
were randomly assigned in a 1 : 1 ratio to receive either 1mg per
day anastrozole administered orally for 6 months (control arm) or
500mg of fulvestrant administered as an intramuscular infusion
every 4 weeks for 6 months with a loading dose in the first month
(experimental arm). Anastrozole (ARIMIDEX, Astra Zeneca,
London, UK) was provided as 1mg film-coated tablets. Fulvestrant
(FASLODEX, Astra Zeneca) was provided as a 250mg/5ml
solution. Before starting treatment, three trucut biopsies were
taken for research purposes; two were frozen and one was fixed in
Molecular Fixative (Hostein et al, 2011). Follow-up was carried out
at 2, 4 and 6 months to assess the clinical response and tolerance.
Drug treatment was continued until the day before surgery.
Surgery at 6 months was proposed to all patients. The decision for
breast-conserving surgery or total mastectomy at the end of
neoadjuvant endocrine treatment was assessed by a multidisci-
plinary board comprising a medical oncologist, a surgeon and a
radiation oncologist. After 6 months of treatment, residual tumour
was resected surgically, and frozen and formalin-fixed samples
were again taken for research purposes. Adjuvant treatments were
decided according to each centre’s policy.
Eligibility. Patients were eligible if they met the following criteria:
post-menopausal woman; histologically confirmed non-metastatic
T2-T3-T4 invasive breast cancer; grade I or II; oestrogen and/or
progesterone-receptor-positive; clinically measurable disease at
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baseline; not eligible for breast-conserving surgery at baseline;
HER2 positive or negative. Women with grade III tumours were
eligible only if they were aged 65 years or over. Patients with
inflammatory breast cancer, N2 disease, a history of cancer within
the past 5 years, or a contra-indication to hormonal therapy were
not eligible.
End points. The primary end point was the objective response
rate (ORR) at 6 months determined by clinical palpation, defined
as the rate of complete and partial responses (CRþPR) according
to RECIST Criteria (Version 1.0). The same doctor was responsible
for clinical assessment initially and at 6 months. Secondary end
points included: ORR determined by ultrasound and mammo-
graphy at 6 months based on RECIST Criteria; rate of breast-
conserving surgery at 6 months; pathological response using the
Sataloff classification (Sataloff et al, 1995); and safety profile
examination using common terminology criteria for adverse events
(CTCAE, version 3.0, DCTD, NCI, NIH; http://ctep.cancer.gov).
Exploratory analyses were carried out for the preoperative
endocrine prognostic index (PEPI score; Ellis et al, 2008) and
changes in the fraction of tumour nuclei expressing Ki-67. Follow-
up was planned for 5 years.
Statistical considerations. The sample size for this non-compara-
tive phase II trial was based on the primary end point, ORR.
According to the Fleming one-step method, for a null hypothesis of
40% ORR and an alternative hypothesis of 60% ORR, 52 assessable
patients needed to be treated in each treatment arm (104 in total),
with a one-sided alpha of 5% and a power of 90%. The
experimental arm was deemed interesting for further research if
at least 27 clinical responses out of 52 treated eligible patients were
observed. This decision rule corresponded to rejecting the null
hypothesis. After adjusting the sample size by 15% to allow for
non-evaluable patients, 120 patients were required. The randomi-
sation was stratified by centre. Two analysis populations were
considered: (i) the safety population, defined as all patients who
received at least one dose of the allocated study medication (a dose
of anastrozole or an injection of fulvestrant), and (ii) the efficacy
population (primary endpoint), defined as all eligible (no major
eligibility deviations) and evaluable patients who started the
allocated treatment and who were evaluated at 6 months. Patients
discontinuing treatment due to progression or death from any
cause were considered as treatment failures. Patients who missed
the evaluation at 6 months due to treatment discontinuation for
toxicity, refusal to participate or lost to follow-up were excluded
from the efficacy population.
Pathological assessment. Ki-67 was scored centrally by a
pathologist (GMG) in a blinded manner according to the
recommendations of Dowsett et al (2011) by counting at least
1000 tumour nuclei per sample after staining with mib1 antibody.
Ki-67 was scored before treatment on the core biopsy and after
treatment on the surgical resection specimen. Tumours were
defined as hormone-receptor positive or negative by local
pathologists with a 10% cutoff for scoring as positive. To evaluate
the pathological response, the Sataloff classification was used
(Sataloff et al, 1995). The PEPI score was calculated as described by
Ellis et al (2008).
Genomic study. Only samples with at least 50% tumour cells after
treatment were selected for the genomic substudy (the tumour cell
content was frequently below this cutoff after treatment). DNA was
purified from frozen samples and analysed on a GAIIx DNA
sequencer (Illumina, San Diego, CA, USA). Low-depth whole-
genome sequencing data were converted to DNA copy number
plots with the CNAnorm package (Gusnanto et al, 2012) in R
statistical software (R Core Team, 2013) as described by (Wood
et al, 2010). Base quality, mapping quality, read depth and tumour
cell content are summarised in Supplementary Table 6, and further
details of the bioinformatics approaches are given in the
Supplementary Methods file.
RESULTS
Baseline characteristics. A total of 120 patients were enrolled in
three French comprehensive cancer centres between March 2008 and
May 2012 and randomly assigned to anastrozole (61 patients, 51%)
or fulvestrant (59 patients, 49%) arm. Two patients withdrew their
consent. Ten patients were not assessable for the efficacy analysis:
four in the standard arm and six in the experimental arm (see
Figure 1 for details). A total of 118 patients and 108 patients were
assessable for the safety and efficacy analyses, respectively (Figure 1).
Patient and tumour characteristics are summarised in Table 1.
Baseline characteristics were balanced between the two treatment
arms, but there were more T2 N0 Grade 1 tumours in the anastrozole
arm and more lobular carcinomas in the fulvestrant arm.
Clinical response and surgery. Of the 56 patients eligible and
evaluable for efficacy in the anastrozole arm, 7 achieved a CR and
26 a PR, giving an ORR of 58.9% (95% CI¼ 45.0–71.9). Of the 52
patients eligible and evaluable for efficacy in the fulvestrant arm,
6 achieved a CR and 22 achieved a PR, giving an ORR of 53.8%
(95% CI¼ 39.5–67.8; Table 2). Analysis including all eligible patients
gave very similar results (Supplementary Table 1). Eight tumours
progressed under therapy: six in the fulvestrant arm and two in the
anastrozole arm. Five patients were HER2-positive at inclusion, of
whom one progressed and four had stable disease. In the
anastrozole arm, 33 patients underwent breast-conserving surgery
(58.9%, 95% CI¼ 45.0–71.9). In the fulvestrant arm, 26 patients
underwent breast-conserving surgery (50.0%, 95% CI¼ 35.8–64.2).
Enrolled patients
(n = 120)
2 Patients not treated
(refusal to continue in study)
Patients assessable for safety
(n = 118)
Patients eligible and assessable for efficacy
(n = 108)
60 Anastrozole 58 Fulvestrant
58 Anastrozole 52 Fulvestrant
10 Patients excluded
– 6 Ineligible
– 4 Missing evaluation at 6 months
Figure 1. Flow chart of patient enrolment and analysis populations.
Two patients withdrew their consent and did not start the allocated
treatment; a total of 118 patients (60 anastrozole and 58 fulvestrant)
were thus assessable for safety. Six patients did not meet the eligibility
criteria: four had grade 3 tumours and were younger than 65 years, one
had an N2 nodal status, and one had bone metastases. A further four
patients were not assessable for the primary end point: one patient
refused both evaluation at 6 months and surgery; two patients stopped
treatment before the 6 months due to toxicity (one elderly patient had
asthenia and vertigo after 4 months of fulvestrant treatment with stable
disease and was offered treatment with anastrozole, and one patient
had musculoskeletal pain after 2 months of anastrozole); and the fourth
patient was lost to follow-up. A total of 108 patients were thus
assessable and eligible for the primary efficacy end point.
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Two patients in the anastrozole arm and six in the fulvestrant arm
did not undergo surgery (see the Supplementary Material for
details); both patients in the anastrozole arm and three in the
fulvestrant arm had a biopsy at 6 months.
Pathological response, ER, PR, Ki67 and PEPI score. Patholo-
gical response data at 6 months for the primary tumour were
available for 92 patients (Table 2). Pathological reports were not
evaluable for eight patients. No complete pathological responses
were observed (Sataloff ‘Tumour A’; Sataloff et al, 1995).
Pathological responses greater than 50% (Sataloff ‘Tumour B’)
were observed in 43% of patients in the anastrozole arm and in
25% of patients in the fulvestrant arm. Nodal status NO (Sataloff
NA or NB) was observed in 34% of patients in the anastrozole arm
and 27% of patients in the fulvestrant arm.
ER scores at baseline and after 6 months of neoadjuvant therapy
were available for 96 patients. The percentage of ER-positive tumour
nuclei in each arm before and after treatment is shown in Figure 2A
and B, with summary statistics in Supplementary Table 2 and Allred
scores in Supplementary Table 3. The figure shows that there was a
large decrease in ER staining in the fulvestrant arm (Wilcoxon test,
Po10 4) but no change in the anastrozole arm (P¼ 0.8). There was
no correlation between ER and clinical response (Figure 2A and B,
and Supplementary Figure 1).
PR scores at baseline and after 6 months of neoadjuvant therapy
were available for 95 patients. The percentage of PR-positive
tumour nuclei in each arm before and after treatment is shown in
Figure 2C and D, with summary statistics in Supplementary
Table 2 and Allred scores in Supplementary Table 3. The figure
shows that there was a large decrease in PR staining in both arms
(fulvestrant arm, Po10 6 ; anastrozole arm, Po10 6). There was
no correlation between PR and clinical response (Figure 2C and D,
and Supplementary Figure 1).
Ki-67 scores at baseline and after 6 months of neoadjuvant
therapy were available for 81 patients. The percentage of Ki-67-
positive tumour nuclei in each arm before and after treatment is
shown in Figure 2E and F. The Ki-67 score fell substantially after
treatment in both arms (Table 3). There was a weak correlation
between the reduction in PR and the reduction in Ki-67 in the
clinical responders in the anastrozole arm (Spearman r¼ 0.46); no
other correlations were observed between Ki-67 and receptor
expression (Supplementary Figure 1). There was no significant
difference between the reduction in Ki-67 in the two arms, or
between the reduction in Ki-67 in clinical responders and non-
responders (Figure 2E and F, Supplementary Figure 1; Wilcoxon
test not significant).
The PEPI score (PEPI for relapse-free survival, Ellis et al, 2008)
after 6 months of therapy was calculated for 76 patients. The
proportion of patients in each of the three PEPI risk subgroups was
broadly similar in both treatment arms (Table 2).
Toxicity. Both treatments were well tolerated. Grade I/II adverse
events occurring inX5% of patients are presented in Supplementary
Table 1. Patient and tumour characteristics
Anastrozole arm Fulvestrant arm
N¼61 (%) N¼59 (%)
Age (years)
Median (range) 69 (54–86) 71 (51–91)
ECOG PS
0 53 (86.9) 49 (83.1)
1 8 (13.1) 10 (16.9)
Tumour size (mm)
Median (range) 45 (25–90) 50 (30–110)
T classification
T2 43 (70.5) 32 (54.2)
T3 9 (14.8) 13 (22.0)
T4 2 (3.3) 8 (13.6)
T4a 0 (0) 1 (1.7)
T4b 6 (9.8) 4 (6.8)
T4c 1 (1.6) 1 (1.7)
N classification
N0 39 (63.9) 29 (49.2)
N1 22 (36.1) 29 (49.2)
NX 0 (0) 1 (1.6)
Histology
Ductal invasive carcinoma 45 (73.8) 39 (66.1)
Lobular invasive carcinoma 14 (23.0) 19 (32.2)
Mucinous adenocarcinoma 2 (3.3) 1 (1.7)
Histologic grades
I 11(18.0) 8 (13.6)
II 45 (73.8) 44 (74.6)
III 3 (4.9) 5 (8.5)
Not available 2 (3.3) 2 (3.4)
Receptor status
ERþ 61 (100) 59 (100)
PRþ 54 (88.5) 55 (93.2)
PR 6 (9.8) 3 (5.1)
PR not available 1 (1.6) 1 (1.7)
HER2a
Positive 4 (6.6) 3 (5.1)
Negative 55 (90.2) 55 (93.2)
Missing 2 (3.3) 1 (1.7)
Abbreviations: ECOG PS¼performance status; ER¼oestrogen receptor; PR¼
progesterone receptor.
aHER2 positive if immunohistochemistry 3þ or if FISH amplified.
Table 2. Clinical and pathological response at 6 months
Anastrozole
arm
Fulvestrant
arm
Clinical response N¼ 56 N¼52
CR 7 (12.5) 6 (11.5)
PR 26 (46.4) 22 (42.3)
SD 21 (37.5) 18 (34.6)
PD 2 (3.6) 6 (11.5)
ORR (CRþPR) 33 (58.9) 28 (53.8)
Surgery N¼ 56 N¼52
Breast-conserving surgery 33 (58.9) 26 (50)
Mastectomy 21 (37.5) 20 (38.5)
No surgery 2 (3.6) 6 (11.5)
Pathological response
Sataloff classification T N¼ 56 N¼52
TB (Pathological response X50%) 24 (42.9) 13 (25.0)
TC 23 (41.1) 24 (46.2)
TD 3 (5.4) 5 (9.6)
Missing 6 (10.7) 10 (19.3)
Sataloff classification N N¼ 56 N¼52
NA 3 (5.4) 6 (11.5)
NB 16 (28.6) 8 (15.4)
NC 20 (35.7) 12 (23.1)
ND 7 (12.5) 15 (28.8)
Missing 10 (17.9) 11 (21.2)
PEPI score N¼ 41 N¼35
0 8 (19.5) 4 (11.4)
1–3 17 (41.5) 19 (54.3)
43 16 (39.0) 12 (34.3)
Abbreviations: CR¼ complete response; NA¼ evidence of therapeutic effect, no residual
disease; NB¼ no evidence of therapeutic effect, no axillary metastasis; NC¼evidence of
therapeutic effect, axillary metastasis present; ND¼ no evidence of therapeutic effect,
axillary metastasis present; ORR¼objective response rate; PD¼progressive disease;
PEPI¼preoperative endocrine prognostic index; PR¼partial response, SD¼ stable disease;
TA¼ complete or nearly complete response; TB¼ therapeutic response over 50%; TC¼
therapeutic response under 50%; TD¼ no evidence of therapeutic effect.
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Table 4. The most common grade 1–2 treatment-related toxicities
were hot flushes (22% in the anastrozole arm and 17% in the
fulvestrant arm) and musculoskeletal pain, which was more
frequent in the anastrozole arm (40%) than in the fulvestrant
arm (21%). Fatigue was more common in the fulvestrant arm (29%
vs 10%) and reaction at the injection site was only reported in the
fulvestrant arm (16%; Supplementary Table 4). Grade 3 muscu-
loskeletal pain was reported in one patient in the anastrozole arm
and grade 3 hot flushes in three patients in the fulvestrant arm.
Four serious adverse events occurred but none were treatment
related: endometrial atrophy, bronchitis and a kidney cancer were
reported in the fulvestrant arm and an ankle fracture after a fall
was reported in the anastrozole arm.
Genomic DNA copy number profiling. The translational study
was performed on samples from 20 patients (labelled H01-H20).
The main criterion for including patients in the translational study
was the availability of material, in particular, the presence of at
least 50% tumour cells in the post-treatment sample. In five cases,
two independent biopsies were tested before treatment and in four
cases two different parts of the surgical specimen were tested after
treatment. In the remaining cases, single samples were tested
before and after treatment. Next-generation sequencing was
performed at low depth and reads were counted in moving
windows to estimate DNA copy number. Hierarchical clustering
was used to detect broad patterns in the data (Figure 3; the
Treeview data files are provided as Supplementary Data to permit
examination of the heatmap at high resolution). As expected for
ERþ breast cancer, many tumours had minimally rearranged
‘simplex’ copy number profiles with gains of 1q/16p and loss of
16q. Apart from H06 and H13, all samples from the same tumour
clustered together. Overall, the clustering shows that the
differences between tumours were in general much greater than
the differences before and after treatment of the same tumour.
Focal differences in tumour profiles before and after treatment.
Eight tumours contained classic amplicons previously reported in
ERþ breast tumours (Supplementary Figure 2). Most amplicons
were present before and after treatment but three tumours (H09,
H14 and H15) showed focal changes in the copy number profile
after treatment. Figure 4B shows the copy number profiles for
tumour H09. Potential driver genes in six amplicons are
highlighted with arrows. The ratio of copy number before and
after treatment for these genes is shown in Figure 4A (the blue dots
are for H09, the other tumours are given black dots). The ratios in
Figure 4A confirm the impression from the profiles in Figure 4B
that new amplicons containing ESR1, ATG5 and MSH2 appeared
after treatment. FISH was used to confirm the presence of the ESR1
amplicon. The gene was highly amplified after treatment
(Figure 4D, green dots), but, unexpectedly, it was also amplified
before treatment (Figure 4C). The green dots are more diffuse
before treatment because an organic fixative was used instead of
formaldehyde, which precludes precise quantification of the
difference. There was no increase in ER staining by IHC after
treatment in H09, perhaps because the signal was already so strong
(Supplementary Table 5). Progesterone receptor was undetectable
by IHC in H09 both before and after treatment (Supplementary
Table 5), as commonly occurs in luminal B tumours. Tumour H14
showed focal changes after treatment, including a copy number
increase after treatment on chr14q in a region containing the
FOXA1 gene (Supplementary Figure 3). Both H09 and H14 were in
the anastrozole arm. In summary, copy number profiles showed
the presence of focal differences in three tumours after treatment,
including two showing changes affecting genes implicated in
oestrogenic signalling (ESR1 and FOXA1).
Large-scale differences in tumour profiles before and after
treatment. We corrected for differences in normal tissue
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Figure 2. Plots showing ER, PR, Ki-67 and response. (A and B)
Oestrogen receptor; (C and D) progesterone receptor; (E and F) Ki-67;
(A, C and E) anastrozole arm; (B, D and F) fulvestrant arm. When points
fall below the diagonal line (y¼ x) in each plot, the measured variable
declined after treatment. At least 1000 tumour cells per tumour were
counted to estimate the percentage with Ki-67-positive nuclei. The
axes are plotted on a log scale for Ki-67 because Ki-67 has a log-normal
distribution. The area of the plotting symbols is proportional to the
number of cases at a given point (e.g., many samples in the anastrozole
arm had 100% ER-positive nuclei before and after treatment, so the
plotting symbols are larger for these values).
Table 3. Ki-67 before and after treatment
Before
treatment (%)
After
treatment (%)
Both arms (n¼81)
Mean 16.9 3.2
95% CI 14.3–20.1 2.2–4.7
Anastrozole arm (n¼43)
Mean 16.7 3.2
95% CI 13.3–21.0 1.9–5.5
Fulvestrant arm (n¼38)
Mean 17.1 3.2
95% CI 13.1–22.5 1.8–5.7
Abbreviation: CI¼ confidence interval Geometric mean and CIs based on logged data
because Ki-67 is log-normal.
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contamination then calculated a Z score for the presence of
large-scale differences between samples, as described in the
Supplementary Methods file and Supplementary Figure 4. Seven
pairs of tumours stood out as being significantly different (H08,
H09, H10, H13, H14, H15 and H19; Supplementary Table 6).
Intriguingly, the commonest change after treatment was not the
appearance of new changes but the disappearance of old ones.
Specifically, in four tumours the profile became simpler through
the disappearance of gains and losses of whole chromosomes or
chromosome arms. We can exclude dilution of the signal by
normal tissue because the 1q gain was still clearly visible in all the
affected tumours. Figure 5A shows tumour H13 in which a gain of
chr7 and losses of chr4, 6, 11, 12, 17 and 18 disappeared, leaving
only the changes on chr1 and 16. Figure 5B shows tumour H08 in
which changes on chr2, 7 and 15 became more normal; the overall
profile shows many other rearrangements that persisted. Figure 5C
shows tumour H10 in which changes on chr3, 13 and 18
disappeared, loss of chr10 and 15 appeared, whereas changes on
chr1, 7, 11, 16 and 22 remained. Figure 5D shows tumour H19 in
which changes on chr3 and 10 disappeared, 20q was gained and
changes on many other chromosomes remained. The differences
after treatment of tumour H06 did not reach significance in our Z
test (Supplementary Table 6), probably because of the low tumour
cell content after treatment, but if chr1 is used as the reference
chromosome in the linear model, chr3, 7, 8, 10, 13 and 18 appear
to have reverted to a more normal profile (Supplementary
Figure 2). Three of the tumours that became simpler showed
stable disease and two a PR; three were in the fulvestrant arm and
two were in the anastrozole arm (Supplementary Table 6). In
summary, genomic profiles showed differences after treatment in
one-third of cases, and the commonest change was a simplification
of the profiles.
DISCUSSION
The main conclusion from this study is that anastrozole and
fulvestrant are effective neoadjuvant treatments for post-meno-
pausal patients with large operable or locally advanced ERþ breast
cancers. Both drugs made breast-conserving surgery a viable
option for some women who were not eligible for it initially. The
main conclusion from the genomic study is that breast tumours
undergoing neoadjuvant endocrine therapy show clonal variation
that could be explained by clonal selection.
The primary clinical end point, the ORR, was 58.9% in the
anastrozole arm and 53.8% in the fulvestrant arm. These figures are
consistent with rates around 50% observed in previous studies
(Eiermann et al, 2001; Mathew et al, 2009; Ellis et al, 2011). The
percentage of women receiving breast-conserving surgery (58.9%
for anastrozole and 50% for fulvestrant) was also similar to that
previously reported after letrozole, anastrozole or tamoxifen (40
and 50%, Eiermann et al, 2001; Smith et al, 2005). In conclusion,
our results are at least as good as those with 3–4 months of
aromatase inhibitors and therefore are consistent with longer
therapy (e.g., 6 months) being better than shorter.
We chose to compare anastrozole with fulvestrant because the
literature does not provide clear guidance on their use in the
neoadjuvant setting (Howell et al, 2004; Smith et al, 2005;
Massarweh et al, 2011; Kuter et al, 2012; Ciruelos et al, 2014).
Comparative studies have demonstrated that both treatments are
effective in the metastatic setting (Mauriac et al, 2003; Robertson
et al, 2012). Aside from the question of efficacy, parenteral
administration of fulvestrant has potential clinical advantages in
patients with swallowing problems or neurological problems, such
as Alzheimer’s disease. Our decision to treat for 6 months was
based on our previous study in elderly or frail women (Mauriac
et al, 2002). It is longer than was initially recommended, but other
groups have now reported favourable outcomes after neoadjuvant
endocrine treatment for up to 7.5 months (Dixon et al, 2009;
Carpenter et al, 2014).
The trend towards prolonging adjuvant hormonal therapy out
to 10 years means there is considerable interest in using
neoadjuvant therapy to provide early evidence of drug efficacy.
Reassessment of drug efficacy after 6 months of neoadjuvant
hormonal therapy provides reassurance that a therapeutic
opportunity is not being lost and could potentially save many
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Figure 3. Heatmap showing hierarchical clustering of the 20 samples
(H01-H20) before (Bx) and after (Ch) treatment. All tumours except
H06Ch2 have abnormalities of chr1 and/or chr16. Colours: yellow,
increase in copy number; blue: decrease in copy number. One node
has been flipped to highlight the differences between H13 before and
after treatment.
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lives. In our study, more tumours had a pathological response over
50% in the anastrozole arm (43%) than in the fulvestrant arm
(25%) but the size of the study and the slight imbalance between
the arms in tumour size, node status and grade at enrolment mean
differences of this size could easily arise by chance. Moreover, the
Sataloff grading system was not originally designed to assess
pathological response to neoadjuvant endocrine therapy and may
not be a good surrogate marker for long-term survival (Dowsett
et al, 2006; Chia et al, 2010). In contrast, changes in Ki67
expression have been widely studied to evaluate the response to
neoadjuvant endocrine therapy (Dowsett et al, 2005; Dowsett et al,
2007; Dowsett et al, 2009; De Censi et al, 2011; Jonat and Arnold,
2011). Most tumours in both arms of our study showed a fall in Ki-
67 after therapy (Figure 2), and the magnitude of the changes was
similar to that associated with favourable outcomes in previous
studies. The similarity of the PEPI scores in the two arms likewise
suggests that patients in the two treatment arms may have similar
long-term outcomes (Dowsett et al, 2005; Ellis et al, 2008).
However, this requires confirmation, especially in the light of
recent data from the FIRST trial, indicating a PFS and OS
advantage for fulvestrant in the metastatic setting (Robertson et al,
2014). Currently, the risk of relapse based on Ki-67 expression or
the PEPI score strongly influences the decision whether to start
adjuvant chemotherapy, but they will become less important if the
ASTER study provides clear-cut evidence that patients over 70
years with high-grade tumours benefit from the addition of
chemotherapy to hormonal therapy.
The most intriguing result from the genomic study was the
simplification of copy number profiles after treatment. It is possible
that these changes were simply a consequence of sampling from
different sites within a clonally heterogeneous tumour. To rule this
out would require high-depth analysis of samples taken from
multiple sites within the surgical specimen. The alternative, and
much more interesting, possibility is that the differences reflect
clonal selection by the treatment. As it is not possible for a tumour
to correct large-scale rearrangements, the most plausible explana-
tion under the clonal-selection hypothesis is that rearranged clones
were eliminated by the treatment, leading to expansion of an
ancestral clone with a related, but simpler, profile. Residual tumour
after neoadjuvant hormonal therapy has previously been noted to
show histological evidence of increased differentiation (Samarnthai
et al, 2012). Transformation is accompanied by subtle changes in
the spectrum of target genes regulated by ERa, leading to a shift
from transcription of tumour-suppressive, differentiation-linked
genes towards the expression of oncogenic genes (Ross-Innes et al,
2012). A possible interpretation of our results is that cells cope with
a reduction in ER-dependent survival signals by reducing the
transcriptional stress associated with chromosomal imbalances.
Clones emerging from such a selection would be more normal:
better able to enter G0, better able to differentiate and more
responsive to oestrogen. This builds on so-called ‘intrinsic tumour
suppression’, a concept that has been extensively characterised in
model systems, in particular in studies on the MYC oncogene
(Lowe et al, 2004). This model is also compatible with the increase
in copy number of ESR1 in H09, which could be viewed as an
adaptive response to offset the reduced availability of oestrogen in
anastrozole-treated cells. That said, the clinical data point rather to
a tumour that is indifferent to oestrogen: there was no change in
tumour size, grade or Ki-67, and PR started at zero and stayed
there. The numbers are too small to meaningfully correlate the
genomic changes we observed with response to therapy, but they
provide no immediate support for the idea that genomic
simplification of heterogeneous tumours is a major resistance
mechanism. In contrast with the variability of chromosomal arm
copy numbers, the classic amplicons known to harbour driver
oncogenes in breast cancer were almost invariably present both
before and after treatment, consistent with the widely accepted
view that breast tumours are addicted to the oncogenes on these
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amplicons. Amplification of ESR1 has a chequered history (Holst
et al, 2007). Given the importance of oestrogen in the biology of
breast cancer cells, ESR1 is an obvious candidate for amplification,
but decades of research point instead to lineage choice as the main
factor leading to ERa expression in breast cancer. Our FISH results
indicate that the appearance of the ESR1 amplicon in the copy
number profile after treatment reflects clonal variation rather than
de novo amplification. This clonal variation could be due to clonal
selection by the treatment or sampling from different regions
within a heterogeneous tumour (a ‘needle placement artefact’), but
whatever the mechanism, we can exclude ESR1 amplification as the
initiating oncogenic event responsible for the ERa positivity of this
tumour.
In conclusion, the good response rates and low toxicity observed
in this study show that both anastrozole and fulvestrant are
effective and well-tolerated neoadjuvant hormonal treatments for
post-menopausal women with large operable or locally advanced
hormone-receptor-positive breast cancer. The results of the
genomic study point to the re-emergence of tumour clones with
less rearranged genomes as a potential new mechanism of
resistance to endocrine therapy, but, given the potential for
sampling effects, larger studies testing multiple biopsies from each
tumour will be required to clarify whether this a reproducible,
clinically important phenomenon.
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